Compare Eli Lilly And Co (LLY) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs T-Mobile Us Inc — how do they compare? Eli Lilly And Co trades at $1,163.81 (market cap $1.02T), while T-Mobile Us Inc trades at $191.69 (market cap $211.72B). The key difference: Eli Lilly And Co is far larger — about 4.8× T-Mobile Us Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| LLY | TMUS | |
|---|---|---|
Market Cap | $1.02T | $211.72B |
Sector | Health | Media |
52-Week High | $1.24K | $259.01 |
52-Week Low | $625.65 | $167.65 |
Enterprise Value | $1.06T | $329.42B |
Dividend Yield | 0.6% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
T-Mobile US (TMUS) trades at $195.37, up 1.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $88.3B revenue in 2025, 11.65% net margin, and consistent earnings beats in three of the last four quarters. Recent leadership changes and strategic appointments position TMUS for growth amid competitive pressures from satellite internet providers.
TMUS presents a compelling investment case with 83% analyst buy ratings and $238.40 consensus target, offering 22% upside. However, rising debt levels (39.35% debt-to-asset ratio) and Starlink competition pose significant risks. The stock's current RSI levels suggest potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
